Drugs in the same class as Ozempic-originally developed to treat type 2 diabetes-are now yielding surprising results in preliminary anti-aging research. A new study from the Chinese University of Hong Kong suggests that exenatide, a GLP-1 receptor agonist like semaglutide, demonstrated improved physical strength and coordination in aging mice, even at doses too low to impact weight. While still in its early stages, this research adds to a growing body of work exploring the potential for these medications to not just manage metabolic diseases, but also to address the biological processes of aging itself [[1]].
Researchers at the Chinese University of Hong Kong treated middle-aged and older mice with exenatide, a type of medication known as a GLP-1 receptor agonist. This class of drugs includes semaglutide, sold under the brand names Ozempic and Wegovy. Surprisingly, the dosage used in the study was so low that the mice experienced minimal weight loss or changes in appetite.
Despite this, the scientists observed significant improvements in the older mice. Compared to mice receiving a placebo, those treated with exenatide demonstrated increased strength and improved performance on motor skill tests. Over six months, their grip strength steadily increased, while the untreated mice became weaker. Their coordination on a rotating cylinder also showed improvement.
Limited Impact on Younger Mice
Interestingly, younger mice showed little to no benefit from the same treatment. The drug appeared to specifically target processes that decline with age, rather than impacting normal biological functions. This suggests the medication doesn’t simply enhance overall health, but rather focuses on counteracting the effects of aging.
The research team also analyzed the effects at a molecular level. They found that changes to DNA typically associated with aging were reversed by the drug across nearly all organs studied. This finding offers a potential new avenue for understanding and addressing age-related decline.
Study Limited to Mice
It’s important to note several limitations to the study. The research was conducted exclusively on male mice, and while the molecular changes were notable, the study did not determine whether the mice lived longer. Cognitive improvements were also limited in the younger test subjects.
The relevance to humans remains unclear. The dose used in the study was significantly lower than those prescribed for obesity treatment. Whether similar effects would occur in people, and at what dosage, requires further investigation. Additionally, the long-term benefits of the drug must be weighed against any potential side effects. Understanding the aging process is a critical area of public health research, and these findings offer a promising starting point for future studies.
